^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer

Published date:
09/02/2022
Excerpt:
Treatment-naive Chinese patients with non-squamous stage IV EGFR/ALK mutation-negative NSCLC were randomized 1:1 to receive 4 or 6 cycles of APP or PP….Among Chinese patients in IMpower132, PFS benefit was seen with APP versus PP.
Secondary therapy:
cisplatin + pemetrexed; carboplatin + pemetrexed
DOI:
https://doi.org/10.1002/cam4.5144
Trial ID: